Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry

Journal of Business Ethics

Volumn 117, Issue 1, 2013, Pages 45-65

  Bruyaka, Olga ^a   Zeitzmann, Hanko K ^a   Chalamon, Isabelle ^b   Wokutch, Richard E ^a   Thakur, Pooja ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b OMNES Education   (France)

Author keywords

Biopharmaceutical industry; Corporate social responsibility (CSR); European Union (EU); Orphan drugs; Rare diseases; Strategic CSR; United States (US)

Indexed keywords

EID: 84884978432     PISSN: 01674544     EISSN: 15730697     Source Type: Journal    
DOI: 10.1007/s10551-012-1496-y     Document Type: Article

References (70)

1. Balotsky, E. R. (2008). Where strategy and ethics converge: Pharmaceutical industry pricing policy for medicare Part D beneficiaries. Journal of Business Ethics, 84, 75-88.
2. Basara, L. R., & Montagne, M. (1994). Searching for magic bullets: Orphan drugs, consumer activism, and pharmaceutical development. Binghamton, NY: Pharmaceutical Products Press (an imprint of The Haworth Press, Inc.).
3. Berthon, P., Lane, N., Pitt, L., & Watson, R. T. (1998). The world wide web as an industrial marketing communication tool: Models for the identification and assessment of opportunities. Journal of Marketing Management, 14(7), 691-704.
4. Bowen, H. R. (1953). Social responsibilities of the businessman. New York: Harper.
5. Burke, L., & Logsdon, J. M. (1996). How corporate social responsibility pays off. Long Range Planning, 29(4), 495-502.
6. Carroll, A. B. (1979). A three-dimensional conceptual model of corporate performance. The Academy of Management Review, 4(4), 497-505.
7. Carroll, A. B. (1991). The pyramid of corporate social responsibility: Toward the moral management of organizational stakeholders. Business Horizons, 34(4), 39-48.
8. Carroll, A. B. (1999). Corporate social responsibility: Evolution of a definitional construct. Business & Society, 38(3), 268-295.
9. Carson, T. (1993). Friedman's theory of corporate social responsibility. Business and Professional Ethics Journal, 12(1), 3-32.
10. Cheah, E. T., Chan, W. L., & Chieng, C. L. L. (2007). The corporate social responsibility of pharmaceutical product recalls: An empirical examination of US and UK markets. Journal of Business Ethics, 76, 427-449.
11. Cheung, R. Y., Cohen, J. C., & Illingworth, P. (2004). Orphan drug policies: Implications for the United States, Canada, and developing countries. Health Law Journal, 12, 183-200.
12. Coupland, C. (2005). Corporate social responsibility as argument on the Web. Journal of Business Ethics, 62(4), 355-366.
13. Davis, K., & Blomstrom, R. L. (1975). Business and society: Environment and responsibility. New York: McGraw-Hill.
14. Deeter-Schmelz, D. R., & Kennedy, K. N. (2002). An exploratory study of the internet as an industrial communication tool: Examining buyers' perceptions. Industrial Marketing Management, 31(2), 145-154.
15. Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007). Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care, 23(01), 36-42.
16. Field, M. J., & Boat, T. F. (2011). Rare diseases and orphan products: Accelerating research and development. Washington, DC: The National Academies Press.
17. Flanagan, W., & Whiteman, G. (2006). "AIDS is not a business:" A study in global corporate responsibility-securing access to low-cost HIV medications. Journal of Business Ethics, 73(1), 65-75.
18. Freeman, S., & Cavusgil, S. T. (2007). Toward a typology of commitment states among managers of born-global firms: A study of accelerated internationalization. Journal of International Marketing, 15(4), 1-40.
19. Friedman, M. (1970). The social responsibility of business is to increase its profits. The New York Times Magazine, 33, 122-126.
20. Fuller, T., & Tian, Y. (2006). Social and symbolic capital and responsible entrepreneurship: An empirical investigation of SME narratives. Journal of Business Ethics, 67(3), 287-304.
21. Gelbmann, U. (2010). Establishing strategic CSR in SMEs: An Austrian CSR quality seal to substantiate the strategic CSR performance. Sustainable Development, 18(2), 90-98.
22. Griffin, J. J., & Mahon, J. F. (1997). The corporate social performance and corporate financial performance debate: Twenty-five years of incomparable research. Business & Society, 36(1), 5-31.
23. Guthrie, D., & Durand, R. (2008). Social issues in the study of management. European Management Review, 5(3), 137-149.
24. Hemphill, T. A. (2009). Extraordinary pricing of orphan drugs: Is it a socially responsible strategy for the US pharmaceutical industry? Journal of Business Ethics, 94(2), 225-242.
25. Huyard, C. (2009). How did uncommon disorders become "rare diseases"? History of a boundary object. Sociology of Health & Illness, 31(4), 463-477.
26. Kak, A. (2008). The eternal orphan. Express Pharma, August 31. Retrieved May 20, 2012 from http://www. expresspharmaonline. com/20080831/research01. shtml.
27. Kumar, R., Lamb, W. B., & Wokutch, R. E. (2002). The end of South African sanctions, institutional ownership, and the stock price performance of boycotted firms: Evidence on the impact of social/ethical investing. Business & Society, 41(2), 133-165.
28. Lazonick, W., & Tulum, Ö. (2011). US biopharmaceutical finance and the sustainability of the biotech business model. Research Policy, 40(9), 1170-1187.
29. Lee, T. W. (1999). Using qualitative methods in organizational research. Thousand Oaks, CA: Sage.
30. Lee, K., Bacchetti, P., & Sim, I. (2008). Publication of clinical trials supporting successful new drug applications: A literature analysis. PLoS Medicine, 5(9), 1348-1356.
31. Leisinger, K. M. (2005). The corporate social responsibility of the pharmaceutical industry: Idealism without illusion and realism without resignation. Business Ethics Quarterly, 15(4), 577-594.
32. Lewellyn, P. G. (2002). Corporate reputation: Focusing the zeitgeist. Business & Society, 41(4), 446-455.
33. Logsdon, J. M., & Wood, D. J. (2002). Reputation as an emerging construct in the business and society field: An introduction. Business & Society, 41(4), 365-370.
34. Maeder, T. (2003). The orphan drug backlash. Scientific American, 288(5), 80-87.
35. Mahon, J. F. (2002). Corporate reputation research agenda using strategy and stakeholder literature. Business & Society, 41(4), 415-445.
36. Maignan, I., & Ralston, D. A. (2002). Corporate social responsibility in Europe and the US: Insights from businesses' self-presentations. Journal of International Business Studies, 33(3), 497-514.
37. Maximiano, J. M. B. (2007). A strategic integral approach (SIA) to institutionalizing CSR. Corporate Social Responsibility and Environmental Management, 14(4), 231-242.
38. McWilliams, A., & Siegel, D. S. (2001). Corporate social responsibility: A theory of the firm perspective. The Academy of Management Review, 26(1), 117-127.
39. McWilliams, A., & Siegel, D. S. (2011). Creating and capturing value: Strategic corporate social responsibility, resource-based theory, and sustainable competitive advantage. Journal of Management, 37(5), 1480-1495.
40. Melnikova, I. (2012). Rare diseases and orphan drugs. Nature Reviews, 11(4), 267-268.
41. Miles, M. B., & Huberman, A. M. (1994). Qualitative data analysis: An expanded sourcebook. Thousand Oaks, CA: SAGE.
42. Miles, M. P., Munilla, L. S., & Darroch, J. (2006). The role of strategic conversations with stakeholders in the formation of corporate social responsibility strategy. Journal of Business Ethics, 69(2), 195-205.
43. Moors, E. H. M., & Faber, J. (2007). Orphan drugs: Unmet societal need for non-profitable privately supplied new products. Research Policy, 36(3), 336-354.
44. Murray, K. B., & Vogel, C. M. (1997). Using a hierarchy-of-effects approach to gauge the effectiveness of corporate social responsibility to generate goodwill toward the firm: Financial versus nonfinancial impacts. Journal of Business Research, 38(2), 141-159.
45. Newman, D. (1992). The great Taxol giveaway. Multinational Monitor, 14(5). http://multinationalmonitor. org/hyper/mm0592. html#taxol. Accessed Sept 20, 2012.
46. Nussbaum, A. K. (2009). Ethical corporate social responsibility (CSR) and the pharmaceutical industry: A happy couple? Journal of Medical Marketing, 9(1), 67-76.
47. O'Riordan, L., & Fairbrass, J. (2008). Corporate social responsibility (CSR): Models and theories in stakeholder dialogue. Journal of Business Ethics, 83(4), 745-758.
48. Orlitzky, M., Schmidt, F. L., & Rynes, S. L. (2003). Corporate social and financial performance: A meta-analysis. Organization Studies, 24(3), 403-441.
49. Pfeffer, J. (1981). Management as symbolic action: The creation and maintenance of organizational paradigms. In L. L. Cummings & B. M. Staw (Eds.), Research in organizational behavior (Vol. 3, pp. 1-52). Greenwich, CT: JAI Press.
50. Porter, M. E., & Kramer, M. R. (2006). Strategy and society: The link between competitive advantage and corporate social responsibility. Harvard Business Review, 84(12), 78-92.
51. Raber, L. R. (2006). Drugs for rare diseases: Patient advocate finds orphan drugs are key to pharma's future. Chemical and Engineering News, June 19. Retrieved from http://pubs. acs. org/cen/pharma/8425meyers. html. Accessed Sept 20, 2012.
52. Ramachandran, V. (2011). Strategic corporate social responsibility: A "dynamic capabilities" perspective. Corporate Social Responsibility and Environmental Management, 18(5), 285-293.
53. Rinaldi, A. (2005). Adopting an orphan. EMBO Reports, 6(6), 507-510.
54. Rindova, V. P., & Fombrun, C. J. (1999). Constructing competitive advantage: The role of firm-constituent interactions. Strategic Management Journal, 20(8), 691-710.
55. Rzakhanov, Z. (2008). Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act. Research Policy, 37(4), 673-689.
56. Schaefer, A. (2004). Corporate sustainability-integrating environmental and social concerns? Corporate Social Responsibility and Environmental Management, 11(4), 179-187.
57. Schwartz, M. S., & Carroll, A. B. (2003). Corporate social responsibility: A three-domain approach. Business Ethics Quarterly, 13(4), 503-530.
58. Siegel, D. S., & Vitaliano, D. F. (2007). An empirical analysis of the strategic use of corporate social responsibility. Journal of Economics & Management Strategy, 16(3), 773-792.
59. Sirsly, C. A. T., & Lamertz, K. (2008). When does a corporate social responsibility initiative provide a first-mover advantage? Business & Society, 47(3), 343-369.
60. Spence, L. J., Schmidpeter, R., & Habisch, A. (2003). Assessing social capital: Small and medium sized enterprises in Germany and the UK. Journal of Business Ethics, 47(1), 17-29.
61. Stolk, P., Willemen, M., & Leufkens, H. G. (2005). Rare essentials? Drugs for rare diseases on the essential medicines list. A discussion paper prepared for the WHO expert committee on the selection and use of essential medicines (pp. 1-22). Utrecht Institute for Pharmaceutical Sciences (UIPS), The Netherlands.
62. Swanson, D. L. (1995). Addressing a theoretical problem by reorienting the corporate social performance model. The Academy of Management Review, 20(1), 43-64.
63. Vachani, S., & Smith, N. C. (2004). Socially responsible pricing: Lessons from the pricing of AIDS drugs in developing countries. California Management Review, 47(1), 117-144.
64. Waddock, S. A., & Graves, S. B. (1997). The corporate social performance-financial performance link. Strategic Management Journal, 18(4), 303-319.
65. Wartick, S. L., & Cochran, P. L. (1985). The evolution of the corporate social performance model. The Academy of Management Review, 10(4), 758-769.
66. Wästfelt, M., Fadeel, B., & Henter, J. I. (2006). A journey of hope: Lessons learned from studies on rare diseases and orphan drugs. Journal of Internal Medicine, 260(1), 1-10.
67. Wizemann, T., Robinson, S., & Giffin, R. (2009). Breakthrough business models: Drug development for rare and neglected diseases and individualized therapies: Workshop summary. Washington, DC: The National Academies Press.
68. Wood, D. J. (1991). Corporate social performance revisited. The Academy of Management Review, 16(4), 691-718.
69. Yin, W. (2008). Market incentives and pharmaceutical innovation. Journal of Health Economics, 27(4), 1060-1077.
70. Yin, W. (2009). R&D policy, agency costs and innovation in personalized medicine. Journal of health economics, 28(5), 950-962.